CANbridge to Continue CAN008 Phase 2 Trial in Glioblastoma Multiforme (GBM) in China Based on Interim Analysis of Independent Data Monitoring Committee

CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company based in China, has announced that it will continue the Phase 2 trial of CAN008 in patients with glioblastoma multiforme (GBM) in China. This decision is based on the interim analysis recommendation of the independent data monitoring committee. The ongoing Phase 2 study aims to evaluate the efficacy and safety of CAN00..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 4.
  • textsms

Delta-Fly Pharma Inc. Provides Schedule for Interim Analysis of Phase 3 Study of DFP-10917 in R/R AML

Delta-Fly Pharma Inc. has announced the schedule for the interim analysis of the Phase 3 study of DFP-10917 in relapsed/refractory acute myeloid leukemia (R/R AML) patients. The interim analysis will be based on outcome measurements including complete remission rate, overall survival, and safety. The first data processing is scheduled to be completed in mid-July 2023, followed by the second data..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 2.
  • textsms

IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone

IO Biotech, a clinical-stage biopharmaceutical company focused on developing immune-modulating cancer vaccines, has achieved a significant milestone in its global Phase 3 clinical trial for IO102-IO103. The company has randomized 225 patients with advanced melanoma in combination with pembrolizumab. The trial protocol calls for an interim analysis of overall response rate one year after the enro..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 15.
  • textsms